- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03104998
Neotililty Trial: Effect of Coenzyme Q10 on Semen Parameters in Men With Idiopathic Infertility (Neotility)
Study Overview
Detailed Description
Decreased serum CoQ10 concentrations as well as a decrease in the CoQ10H2 to-ubiquinone ratio have been demonstrated in diseases associated with OS. A strong correlation among sperm count, motility and ubiquinol-10 levels in seminal fluid has also been reported.
The aim of the present study is to investigate whether the effects of the exogenous administration of ubiquinol in the improvement of semen parameters in Pakistani men population.
Patients who full filled the inclusion criteria and gave informed written consent will be included in the trial. Patient will start to take medication and will take it for 26 weeks.
All men undergo a thorough physical examination, a detail history, serum biochemical and hematological laboratory tests and measurement of serum sex and thyroid hormone levels. A questionnaire will be used to collect information on demographic characteristics. Two semen samples 1 and 2 month apart will be obtained after 3 to 5 days of sexual abstinence and process within 1 hour of ejaculation. The mean of the two will be used for statistical analysis. Semen analyses will be performed using WHO recommended methods.
3 ml of blood will be withdrawn from the patient for the serum hormones analysis and total amount of semen will required for analysis of semen parameters.
Sponsor will bear the test cost of patient during the study treatment period.
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Karachi, Pakistan
- HillPark Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- To sign the Informed Consent form
- Patients will be recruited in the study if they will fulfilled the criteria of history of primary infertility of more than 2 years, abnormal sperm count and motility
- age between 20 and 50 years
- No known medical or surgical condition which can result in infertility
Exclusion Criteria:
- Voluntary withdrawal
- Poor compliance of visit/treatment
- A history of cancer chemotherapy or radiotherapy
- A history of genital disease such as cryptorchidism and varicocele; a history of genital surgery
- Body mass index 30 kg/m or greater; any endocrinopathy
- Ychromosome microdeletions or karyotype abnormalities
- leukocytospermia
- Drug or substance abuse; tobacco use;
- Use of anticonvulsants, androgens or antiandrogens
- Significant liver (serum bilirubin greater than 2.0 mg/dl)
- Renal function (serum creatinine greater than 2.0 mg/dl) impairment
- Patients with severe oligozoospermia (less than 5 X 106/ml), azoospermia and testicular volume less than 12 ml will also excluded from study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: coenzyme Q10
Dose of 200 mg of CoQ10 taken daily by mouth from day 1 till 26 weeks
|
200 mg of CoQ10 or placebo daily by mouth from day 1 till 26 weeks.
CoQ10 treatment is safe, even at the highest doses cited in the literature.
Most clinical trials have not reported significant adverse effects that necessitated stopping therapy.
However, gastrointestinal effects such as abdominal discomfort, nausea, vomiting, diarrhea, and anorexia have occurred.
Allergic rash and headache have also been reported
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure the change in semen parameters after 26 Weeks of coenzyme q10.
Time Frame: 26 weeks
|
To measure the change in semen parameters after 26 Weeks of coenzyme q10. Designated as safety issue: No |
26 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Event
Time Frame: 26 weeks
|
Proportion of participants experiencing an adverse event (AE) leading to permanent discontinuation of study medication [Designated as safety issue: Yes]
|
26 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Masood Jawaid, MRCS,FCPS, PharmEvo Pvt Ltd
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PE/PK/Neotility/SP/2017-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Idiopathic Infertility
-
Arak University of Medical SciencesNot yet recruiting
-
Ludwig-Maximilians - University of MunichEssex Pharma GmbH; Organon GmbH (former name)Completed
-
Ferring PharmaceuticalsRecruitingMale Idiopathic InfertilityDenmark, United States, Sweden, Belgium, Spain, Italy, Germany
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Sapientiae InstituteTerminated
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
King's College LondonNot yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
Clinical Trials on Coenzyme Q10
-
University of SumerCompletedMale InfertilityIraq
-
University of ShizuokaCompletedHemodialysis | Chronic Renal FailureJapan
-
Central Hospital, Nancy, FranceCompletedCyclic Vomiting SyndromeFrance
-
Columbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)CompletedAmyotrophic Lateral Sclerosis | Lou Gehrig's DiseaseUnited States
-
Hadassah Medical OrganizationUnknown
-
Peter HumaidanCompleted
-
Johns Hopkins UniversityNational Institute of Neurological Disorders and Stroke (NINDS)CompletedHuntington's DiseaseUnited States
-
Technische Universität DresdenDeutsche Parkinson-Vereinigung e.V.; MSE Pharmazeutika GmbH, Bad HomburgCompleted
-
Mclean HospitalNational Alliance for Research on Schizophrenia and DepressionCompleted
-
National University Hospital, SingaporeCompletedParkinson DiseaseSingapore